Launch of Innovative Medicines Initiative Programme to Help Respond to Ebola Crisis

2014 11 06 Written by Vaccines Europe

Vaccines Europe is pleased to announce today the launch of Ebola+, the Innovative Medicines Initiative (IMI2) Programme Call to Help Responding to the Ebola Virus Disease (EVD) Crisis. This EUR 280 Million call is expected to bring together pharmaceutical and vaccine companies and researchers working in the space of Ebola andĀ haemorragic fevers prevention and treatment leveraging the already on-going investments to address the current outbreak in West Africa.

Vaccines Europe President Andrea Rappagliosi stated today that “The vaccine industry stands firm to play its role in the fight against Ebola, and is committed to this IMI Ebola Programme, which will help to address the challenges in developing the needed vaccines”.

For more information on the call and its launch, please read the EFPIA Press Release.